News

InvestorsHub on MSN2d
Hims & Hers Shares Gain on Plans for Canadian Launch Featuring Generic Semaglutide
Hims & Hers Health (NYSE:HIMS) shares climbed 2% on Wednesday following the announcement of its planned market entry into ...
Hims & Hers’ ugly split with Wegovy maker weighs on the telehealth company’s future
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Market Voices: Copper tariffs, mortgage volumes rise, Hims & Hers
Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...
StockStory.org on MSN2d
Hims & Hers Health (HIMS) Stock Is Up, What You Need To Know
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...
Hims & Hers Health: Unlocking A $6 Billion Future
Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...
Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers
U.S. telehealth platform looks to take advantage of Ozempic patent expiring in January, while four manufacturers filed for ...
Hims & Hers Times Pivot to Canada With Generic Weight-Loss Drug After Wegovy Fallout -- Update
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...